Rating on Array BioPharma (NASDAQ:ARRY) is Set to Outperform. Its Reconfirms by Wells Fargo with $33 Target.

June 29, 2018 - By Clara Lewis

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo

Big Money Sentiment increased to 1.74 in 2018 Q1. It has change of 0.44, from 2017Q4’s 1.3. The ratio is positive due to Array BioPharma Inc. positioning: 16 sold and 54 reduced. 55 funds acquired stakes and 67 increased stakes. Investors holded 194.11 million in 2017Q4 but now own 189.71 million shares or 2.27% less.

Quantitative Systematic Strategies Limited Liability has 0.05% invested in Array BioPharma Inc. (NASDAQ:ARRY). 40,133 were reported by Perceptive Advsrs. Prelude Capital Mngmt Ltd Co reported 46,252 shs stake. Pinnacle Assoc Limited holds 0.83% or 2.60 million shs in its capital. Thompson Davis And Co, Virginia-based fund reported 125 shs. Moreover, Parametric Assocs Llc has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 207,628 shs. Nj State Employees Deferred Compensation Plan, a New Jersey-based fund reported 20,000 shs. Creative Planning holds 0% or 31,888 shs in its capital. D E Shaw And accumulated 14,218 shs or 0% of the stock. Columbus Circle Investors stated it has 1.13 million shs. North Star Corp reported 0.14% in Array BioPharma Inc. (NASDAQ:ARRY). Century accumulated 1.59M shs. Meeder Asset Incorporated reported 737 shs or 0% of all its holdings. Sg Americas Limited Company holds 16,065 shs. Bain Cap Pub Equity Mngmt Limited Liability invested 0.18% of its capital in Array BioPharma Inc. (NASDAQ:ARRY).

Array BioPharma Inc. had 11 selling transactions and 0 buys since January 16, 2018. This’s net activity of $6.95 million. 7,500 shs valued at $102,975 were sold by Haddock Jason on Tuesday, January 16. On Friday, March 9 Sandor Victor sold $2.76M worth of Array BioPharma Inc. (NASDAQ:ARRY).

Reiterated Array BioPharma (NASDAQ:ARRY) Rating.

Wells Fargo’s Expert analysts have $33 target price which means upside potential of 98.08 % on Array BioPharma (NASDAQ:ARRY). a research note of the firm was disclosed on Thursday, 28 June.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

A total of 7 analysts rate Array Biopharma (NASDAQ:ARRY) as follows: 7 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:ARRY) has 13 ratings reports on Jun 29, 2018 according to StockzIntelligence. On Thursday, June 28 Wells Fargo maintained Array BioPharma Inc. (NASDAQ:ARRY) rating. Wells Fargo has “Outperform” rating and $33 target. On Monday, June 25 the firm has “Buy” rating by Piper Jaffray given. On Tuesday, February 6 the company was maintained by Stifel Nicolaus. On Monday, June 25 Cantor Fitzgerald maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Overweight” rating. The stock rating was maintained by Cowen & Co with “Buy” on Thursday, May 10. On Tuesday, February 6 the rating was maintained by SunTrust with “Buy”. On Wednesday, February 7 Leerink Swann maintained Array BioPharma Inc. (NASDAQ:ARRY) with “Outperform” rating. The stock rating was maintained by Cowen & Co with “Buy” on Tuesday, June 5. On Sunday, January 21 the company was maintained by Cowen & Co. On Wednesday, February 7 the rating was maintained by Cowen & Co with “Buy”.

Ticker’s shares touched $16.66 during the last trading session after 1.42% change.Currently Array BioPharma Inc. is uptrending after 92.14% change in last June 29, 2017. ARRY has also 1.40M shares volume. ARRY outperformed the S&P500 by 79.57%.

Array BioPharma Inc. (NASDAQ:ARRY)’s earnings report is expected on August, 8., as reported by RTT. Last year’s EPS was $-0.17, while now analysts expect change of 47.06 % down from current $-0.25 EPS. After $-0.11 EPS report previous quarter, Wall Street now predicts 127.27 % negative EPS growth of Array BioPharma Inc..

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The company has $3.51 billion market cap. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Last it reported negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

For more Array BioPharma Inc. (NASDAQ:ARRY) news brought out recently go to: Benzinga.com, Fool.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” brought out on June 28, 2018, “George Soros Bought This Clinical-Stage Biotech Stock. Should You?” on May 31, 2018, “Key events next week – healthcare” with a publish date: June 21, 2018, “3 Biotechs With Huge FDA Decisions in June” and the last “Jordyn Fantuzzi” with publication date: June 28, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.